Antonio Aponte Gracia
Hematology & Oncology · Mayaguez, PRNPI 1902968209
Payments from drug & device makers
Across 146 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Eli Lilly Export S.A. Puerto Rico Branch$788
- Johnson & Johnson$374
- Clovis Oncology, Inc.$162
- Bristol Myers Squibb$114
- AbbVie$112
- plus $422 from 8 others
What the payments were for
- Food & beverage$2,80388%
- Education$39412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 77 | $1,226 |
| Eli Lilly Export S.A. Puerto Rico Branch | 29 | $788 |
| Johnson & Johnson(2 entities) | 8 | $374 |
| Clovis Oncology, Inc. | 3 | $162 |
| Bristol Myers Squibb | 5 | $114 |
| AbbVie | 7 | $112 |
| Merck | 5 | $97 |
| GSK | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $63 |
| Amgen | 1 | $52 |
| Sanofi | 2 | $45 |
| AstraZeneca | 2 | $40 |
| PBG Puerto Rico LLC | 2 | $34 |
| Seagen Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rubraca$125
How this compares
$3,197 in reported general payments places this provider in the 20th percentile of 138 hematology & oncology providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 24 | $377,628 |
| ImbruvicaIbrutinib | 14 | $223,347 |
| RevlimidLenalidomide | 12 | $219,722 |
| TagrissoOsimertinib Mesylate | 11 | $189,532 |
| RetacritEpoetin Alfa-Epbx | 26 | $35,348 |
| Exemestane | 59 | $2,774 |
| Imatinib Mesylate | 19 | $1,768 |
| Hydroxyurea | 44 | $1,392 |
| SynthroidLevothyroxine Sodium | 22 | $1,132 |
| Anastrozole | 47 | $618 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 19 | $570 |
| Omega-3 Acid Ethyl Esters | 13 | $397 |
| Omeprazole | 28 | $184 |
| Sulindac | 13 | $144 |
| Gabapentin | 17 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $114 | $219,72212 claims |
| AstraZenecaTagrisso | $40 | $189,53211 claims |
| AbbVieSynthroid | $112 | $1,13222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Mayaguez
- Christian RolonMayaguez$32K
- Erick CruzMayaguez$20K
- Mirelis AcostaSan Juan$6.3M
- Hector Velez CortesPonce$3.1M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
- Adelba Torres-LopezSan Juan$1.9M
- Maria Garcia PallasCaguas$1.8M
- Karina Arocho-GonzalezHato Rey$1.1M
- Jose Lozada CostasSan Juan$934K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.